Immune mediated Diseases-Vaccines

Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis, are at increased risk of infection, partially because of the disease itself, but mostly because of treatment with immunomodulatory or immunosuppressive drugs. In spite of their elevated risk for vaccine-preventable disease, vaccination coverage in IMID patients is surprisingly low. This review summarizes current literature data on vaccine safety and efficacy in IMID patients treated with immunosuppressive or immunomodulatory drugs and formulates best-practice recommendations on vaccination in this population. Especially in the current era of biological therapies, including TNF-blocking agents, special consideration should be given to vaccination strategies in IMID patients. Clinical evidence indicates that immunization of IMID patients does not increase clinical or laboratory parameters of disease activity. Live vaccines are contraindicated in immunocompromized individuals, but non-live vaccines can safely be given. Although the reduced quality of the immune response in patients under immunotherapy may have a negative impact on vaccination efficacy in this population, adequate humoral response to vaccination in IMID patients has been demonstrated for hepatitis B, influenza and pneumococcal vaccination. Vaccination status is best checked and updated before the start of immunomodulatory therapy: live vaccines are not contraindicated at that time and inactivated vaccines elicit an optimal immune response in immunocompetent individuals.

Vaccines: Following the great success of the 5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, July 27-28, 2015 Brisbane, AustraliaOMICS Group International is organizing the 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination which is going to be held in Melbourne, Australia in 2016. This will be the latest in the OMICS group annual vaccine meeting series with 500 Plus Attendees, to provide a forum where key vaccine stakeholders including academic researchers, public health clinicians, veterinarians, vaccine policy makers, and manufacturers can exchange ideas and collaborate. There will be opportunities for those chosen to present at the meeting to publish a manuscript based on their presentation in the Journal of Vaccines & Vaccination or its sister publication, Immunome Research.

Related Conferences: Children Vaccines 2016 Oct 10-12, 2016 Rome, Italy; International Conference on H1N1 & Influenza Vaccines July 25-26, 2016 Chicago, USA; International Conference on Hepatitis Vaccines Conference June 16-18, 2016 Rome, Italy; Annual Conference on Virulent Hiv Vaccines Conference Oct 3-5, 2016 Miami, USA; 10th Euro Global Summit and Expo on Vaccines & Vaccination 16-18, 2016 Rome, Italy; 13th Vaccines Asia Pacific Global summit and Expo on Vaccines & Vaccination Conference November 03-05, 2016 Melbourne, Australia;   Keystone Symposia Advancing Vaccines in the Genomics Era (T1) Rio de Janeiro, Brazil; 2nd Annual Biologics World Taiwan Taipei, Taiwan; 2nd Antivirals Congress Massachusetts, United States; Isocyanates and Health Past, Present and Future Maryland, United States; International Conference on Clinical and Cellular Immunology Chicago-North Shore, United;  Keystone Symposia HIV Vaccines Colorado, United States

Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis, are at increased risk of infection, partially because of the disease itself, but mostly because of treatment with immunomodulatory or immunosuppressive drugs. In spite of their elevated risk for vaccine-preventable disease, vaccination coverage in IMID patients is surprisingly low. This review summarizes current literature data on vaccine safety and efficacy in IMID patients treated with immunosuppressive or immunomodulatory drugs and formulates best-practice recommendations on vaccination in this population. Especially in the current era of biological therapies, including TNF-blocking agents, special consideration should be given to vaccination strategies in IMID patients. Clinical evidence indicates that immunization of IMID patients does not increase clinical or laboratory parameters of disease activity. Live vaccines are contraindicated in immunocompromized individuals, but non-live vaccines can safely be given. Although the reduced quality of the immune response in patients under immunotherapy may have a negative impact on vaccination efficacy in this population, adequate humoral response to vaccination in IMID patients has been demonstrated for hepatitis B, influenza and pneumococcal vaccination. Vaccination status is best checked and updated before the start of immunomodulatory therapy: live vaccines are not contraindicated at that time and inactivated vaccines elicit an optimal immune response in immunocompetent individuals.

Vaccines: Following the great success of the 5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, July 27-28, 2015 Brisbane, AustraliaOMICS Group International is organizing the 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination which is going to be held in Melbourne, Australia in 2016. This will be the latest in the OMICS group annual vaccine meeting series with 500 Plus Attendees, to provide a forum where key vaccine stakeholders including academic researchers, public health clinicians, veterinarians, vaccine policy makers, and manufacturers can exchange ideas and collaborate. There will be opportunities for those chosen to present at the meeting to publish a manuscript based on their presentation in the Journal of Vaccines & Vaccination or its sister publication, Immunome Research.

Related Conferences: Children Vaccines 2016 Oct 10-12, 2016 Rome, Italy; International Conference on H1N1 & Influenza Vaccines July 25-26, 2016 Chicago, USA; International Conference on Hepatitis Vaccines Conference June 16-18, 2016 Rome, Italy; Annual Conference on Virulent Hiv Vaccines Conference Oct 3-5, 2016 Miami, USA; 10th Euro Global Summit and Expo on Vaccines & Vaccination 16-18, 2016 Rome, Italy; 13th Vaccines Asia Pacific Global summit and Expo on Vaccines & Vaccination Conference November 03-05, 2016 Melbourne, Australia;   Keystone Symposia Advancing Vaccines in the Genomics Era (T1) Rio de Janeiro, Brazil; 2nd Annual Biologics World Taiwan Taipei, Taiwan; 2nd Antivirals Congress Massachusetts, United States; Isocyanates and Health Past, Present and Future Maryland, United States; International Conference on Clinical and Cellular Immunology Chicago-North Shore, United;  Keystone Symposia HIV Vaccines Colorado, United States

  • Auto Immune Diseases- Vaccines
  • Immunization In Immuno-compromised People
  • Latest Vaccine Development
  • Complications In Hiv Patients
  • Others

Related Conference of Immune mediated Diseases-Vaccines

July 27-28, 2018

31st Annual Congress on Vaccines & Clinical Trials

Vancouver, Canada
October 01-03, 2018

Vaccine R&D: International Vaccine Congress

Dubai, UAE
October 22-23, 2018

30th World Congress on Vaccines and Immunization

Osaka, Japan

Immune mediated Diseases-Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in